Naratriptan Migräne STADA

Naratriptan Migräne STADA Uses, Dosage, Side Effects, Food Interaction and all others data.

Naratriptan Migräne STADA is a triptan drug that is selective for the 5-hydroxytryptamine1 receptor subtype. It is typically used for the treatment of migraine headaches.

Naratriptan Migräne STADA is a selective agonist of serotonin (5-hydroxytryptamine; 5-HT) type 1B and 1D receptors. It is structurally and pharmacologically related to other selective 5-HT1B/1D receptor agonist. Naratriptan Migräne STADA has only a weak affinity for 5-HT1A, 5-HT5A, and 5-HT7 receptors and no significant affinity or pharmacological activity at 5-HT2, 5-HT3 or 5-HT4 receptor subtypes or at alpha1-, alpha2-, or beta-adrenergic, dopamine1,; dopamine2; muscarinic, or benzodiazepine receptors. This action in humans correlates with the relief of migraine headache. In addition to causing vasoconstriction, experimental data from animal studies show that Naratriptan Migräne STADA also activates 5-HT1 receptors on peripheral terminals of the trigeminal nerve innervating cranial blood vessels, which may also contribute to the antimigrainous effect of Naratriptan Migräne STADA in humans.

Naratriptan Migräne STADA
Uses
Dosage
Side Effect
Precautions
Interactions
Uses during Pregnancy
Uses during Breastfeeding
Accute Overdose
Food Interaction
Half Life
Volume of Distribution
Clearance
Interaction With other Medicine
Contradiction
Storage

Trade Name	Naratriptan Migräne STADA
Availability	Prescription only
Generic	Naratriptan
Naratriptan Other Names	Naratriptán, Naratriptan, Naratriptanum
Related Drugs	Ubrelvy, Botox, diclofenac, celecoxib, metoclopramide, sumatriptan, Imitrex, Reglan
Type
Formula	C₁₇H₂₅N₃O₂S
Weight	Average: 335.464 Monoisotopic: 335.166747749
Protein binding	28%-31% (over the concentration range of 50 to 1000 ng/mL)
Groups	Approved, Investigational
Therapeutic Class
Manufacturer
Available Country	Germany
Last Updated:	September 19, 2023 at 7:00 am

Uses

Naratriptan Migräne STADA is a 5-HT1B/1D receptor agonist used to treat migraines.

For the acute treatment of migraine attacks with or without aura in adults.

Naratriptan Migräne STADA is also used to associated treatment for these conditions: Migraine with acute onset aura, Acute Migraine without aura

How Naratriptan Migräne STADA works

Three distinct pharmacological actions have been implicated in the antimigraine effect of the triptans: (1) stimulation of presynaptic 5-HT1D receptors, which serves to inhibit both dural vasodilation and inflammation; (2) direct inhibition of trigeminal nuclei cell excitability via 5-HT1B/1D receptor agonism in the brainstem and (3) vasoconstriction of meningeal, dural, cerebral or pial vessels as a result of vascular 5-HT1B receptor agonism.

Toxicity

Symptoms of overdose include light-headedness, loss of coordination, tension in the neck, and tiredness.

Food Interaction

Take with or without food. The absorption is unaffected by food.

Naratriptan Migräne STADA Cholesterol interaction

[Major] The group of drugs known as 5-hydroxytryptamine1 receptor (5-HT1) agonists can cause vasospastic reactions, including coronary vasospasm, peripheral vascular ischemia, and colonic ischemia.

Rarely, serious adverse cardiac events including acute myocardial infarction, arrhythmia, cardiac arrest, and death have been reported within a few hours following the administration of 5-HT1 agonists, in some cases even in patients with no prior history or findings of coronary artery disease (CAD).

Significant elevation in blood pressure, including hypertensive crisis, has also been reported on rare occasions in patients with and without a history of hypertension, as have transient increases in blood pressure and peripheral vascular resistance.

In general, patients with potentially unrecognized CAD as predicted by the presence of risk factors (e.g., hypertension, hypercholesterolemia, tobacco use, obesity, diabetes, strong family history of CAD, female with surgical or physiological menopause, or male over 40 years of age) should not be administered 5-HT1 agonists unless a cardiovascular evaluation provides satisfactory clinical evidence indicating the lack of CAD, ischemic heart disease, or other significant underlying cardiovascular disease.

As a precaution, the manufacturers recommend that the first dose be administered under medical surveillance in such patients, and that electrocardiographic monitoring be considered during the interval immediately following administration to help detect any asymptomatic cardiac ischemia that may occur.

Periodic cardiovascular evaluations should be performed during intermittent, long-term use.

Naratriptan Migräne STADA Drug Interaction

Major: duloxetine, duloxetine, ondansetron, ondansetronUnknown: diphenhydramine, diphenhydramine, galcanezumab, galcanezumab, pregabalin, pregabalin, rimegepant, rimegepant, topiramate, topiramate, cyanocobalamin, cyanocobalamin, cholecalciferol, cholecalciferol, cetirizine, cetirizine

Naratriptan Migräne STADA Disease Interaction

Major: CAD risk factors, cardiovascular disease, liver disease, renal dysfunction

Volume of Distribution

170 L

Elimination Route

Well absorbed (74% oral biovaility), absorption is rapid with peak plasma concentrations after 2-5 hours. The rate of absorption is slower during a migraine attack.